Nektar Therapeutics Management
Management criteria checks 3/4
Nektar Therapeutics' CEO is Howard Robin, appointed in Jan 2007, has a tenure of 17.83 years. total yearly compensation is $3.14M, comprised of 34.6% salary and 65.4% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth €653.49K. The average tenure of the management team and the board of directors is 5.8 years and 16.3 years respectively.
Key information
Howard Robin
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 34.6% |
| CEO tenure | 17.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 5.8yrs |
| Board average tenure | 16.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$168m |
| Jun 30 2024 | n/a | n/a | -US$177m |
| Mar 31 2024 | n/a | n/a | -US$176m |
| Dec 31 2023 | US$3m | US$1m | -US$276m |
| Sep 30 2023 | n/a | n/a | -US$294m |
| Jun 30 2023 | n/a | n/a | -US$307m |
| Mar 31 2023 | n/a | n/a | -US$415m |
| Dec 31 2022 | US$11m | US$1m | -US$368m |
| Sep 30 2022 | n/a | n/a | -US$454m |
| Jun 30 2022 | n/a | n/a | -US$525m |
| Mar 31 2022 | n/a | n/a | -US$491m |
| Dec 31 2021 | US$11m | US$1m | -US$524m |
| Sep 30 2021 | n/a | n/a | -US$495m |
| Jun 30 2021 | n/a | n/a | -US$474m |
| Mar 31 2021 | n/a | n/a | -US$429m |
| Dec 31 2020 | US$11m | US$1m | -US$444m |
| Sep 30 2020 | n/a | n/a | -US$439m |
| Jun 30 2020 | n/a | n/a | -US$429m |
| Mar 31 2020 | n/a | n/a | -US$460m |
| Dec 31 2019 | US$10m | US$1m | -US$441m |
| Sep 30 2019 | n/a | n/a | -US$427m |
| Jun 30 2019 | n/a | n/a | -US$424m |
| Mar 31 2019 | n/a | n/a | US$657m |
| Dec 31 2018 | US$13m | US$969k | US$681m |
| Sep 30 2018 | n/a | n/a | US$746m |
| Jun 30 2018 | n/a | n/a | US$903m |
| Mar 31 2018 | n/a | n/a | -US$129m |
| Dec 31 2017 | US$18m | US$941k | -US$97m |
Compensation vs Market: Howard's total compensation ($USD3.14M) is above average for companies of similar size in the German market ($USD846.96K).
Compensation vs Earnings: Howard's compensation has been consistent with company performance over the past year.
CEO
Howard Robin (71 yo)
17.8yrs
Tenure
US$3,135,576
Compensation
Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 17.8yrs | US$3.14m | 0.37% € 653.5k | |
| Chief Financial Officer | 1.6yrs | US$376.30k | no data | |
| Senior VP | 8.3yrs | US$1.10m | 0.12% € 212.3k | |
| Chief Research & Development Officer | 5.1yrs | US$1.77m | 0.13% € 235.7k | |
| Director of Investor Relations & Corporate Affairs | no data | no data | no data | |
| Senior Vice President of Human Resources & Facilities Operations | 2.9yrs | no data | no data | |
| Chief Business Officer | 5.8yrs | no data | no data | |
| Chief Medical Officer | 7yrs | no data | no data |
5.8yrs
Average Tenure
58yo
Average Age
Experienced Management: ITH's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 17.8yrs | US$3.14m | 0.37% € 653.5k | |
| Independent Chairman of the Board | 32.5yrs | US$176.22k | 0.14% € 253.7k | |
| Independent Director | 14.8yrs | US$170.22k | 0.16% € 294.4k | |
| Lead Independent Director | 24.3yrs | US$170.22k | 0.16% € 279.1k | |
| Independent Director | 7.2yrs | US$134.22k | 0.019% € 33.1k | |
| Independent Director | 3yrs | US$112.72k | 0.012% € 21.8k |
16.3yrs
Average Tenure
66.5yo
Average Age
Experienced Board: ITH's board of directors are seasoned and experienced ( 16.3 years average tenure).